Please enable Javascript
Prostate Cancer Diagnostics
Advertisement
Genomic Signatures Associated With Adverse Pathologic Features at Radical Prostatectomy
Eric Li, MD
Prostate Cancer Diagnostics
|
May 8, 2024
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
View More
Prostate Cancer Screening in High-Risk Groups: Challenges to Equitable and Pragmatic Screening
Yaw A. Nyame, MD, MS, MBA
Prostate Cancer Diagnostics
|
May 7, 2024
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
View More
Determining Best Candidates for Concomitant ADT in Prostate Cancer
Katy Marshall
Prostate Cancer Diagnostics
|
May 3, 2024
The utility of cADT in patients with prostate cancer with clinical relapse at PSMA PET is unknown.
Read More
Navigating Genomic Testing in Prostate Cancer: A Comprehensive Guide for Precision Treatment
Gillian Vandekerkhove, PhD
Prostate Cancer Diagnostics
|
April 25, 2024
Dr. Vandekerkhove explains her research on genomic testing in prostate cancer.
View More
New Noninvasive Urine Test Can Reduce Unnecessary Biopsies in Advanced Prostate Cancer
Emily Menendez
Prostate Cancer Diagnostics
|
April 24, 2024
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
Read More
68Ga-RM2 PET-MRI Versus MRI Alone for Biochemically Recurrent Prostate Cancer
Andrei Iagaru, MD
Prostate Cancer Diagnostics
|
April 16, 2024
Dr. Iagaru discusses the safety findings and clinical implications of his research.
View More
Prostate Cancer Molecular Imaging and Therapy in MIRROR and 177Lu-PNT2002 Trials
Gary Ulaner, MD, PhD, FSNMMI, FACNM
Prostate Cancer Diagnostics
|
April 16, 2024
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
View More
Leonard Gomella, MD, FACS – A Decades-Long Commitment to Advancing Urology
Leonard Gomella, MD, FACS
Prostate Cancer Diagnostics
|
April 10, 2024
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Read More
PI-RADS, PSAD Data Can Prevent Unnecessary Biopsy in Prostate Cancer Patients
Emily Menendez
Prostate Cancer Diagnostics
|
April 10, 2024
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Read More
Progress Continues for Use of Liquid Biopsies in GU Cancers
Leah Lawrence
Prostate Cancer Diagnostics
|
April 8, 2024
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Read More
First Patient Treated in Cohort 4 of Clarity Pharmaceuticals’ SECuRE Trial
Katy Marshall
Prostate Cancer Diagnostics
|
March 25, 2024
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
Read More
PSMA PET for BCR Salvage RT Management: Projecting Survival Data and Additional Research Avenues
Jérémie Calais, MD, PhD
Prostate Cancer Diagnostics
|
March 21, 2024
The panel continues discussing their phase 3 PSMA PET/CT trial expectations for the final data readout in 2025.
View More
Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management
Jérémie Calais, MD, PhD
Prostate Cancer Diagnostics
|
March 21, 2024
The panel from UCLA highlights their study on the impact of PSMA PET/CT on prostate cancer salvage radiotherapy management.
View More
Clarity Pharmaceuticals’ SECuRE Trial Progresses to Multi-Dose Phase
Katy Marshall
Prostate Cancer Diagnostics
|
March 15, 2024
Cohort 3 of the theranostic trial tested a 64Cu/67Cu-SAR-bisPSMA 12-GBq dose in 6 participants with mCRPC.
Read More
68Ga-RM2 PET-MRI Provides Higher Detection Rates Than MRI Alone for Biochemically Recurrent Prostate Cancer
Emily Menendez
Prostate Cancer Diagnostics
|
March 6, 2024
Gastrin-releasing peptide receptors may be overexpressed in prostate cancer.
Read More
Updated COBRA Results Show SAR-bisPSMA Detects Smaller Lesions
Zachary Bessette
Prostate Cancer Diagnostics
|
March 6, 2024
Clarity released updated data on COBRA, confirming that 64Cu-SAR-bisPSMA leads to higher detection of lesions in BCR.
Read More
Evaluating Intraductal Prostate Cancer Using PSMA PET
Katy Marshall
Prostate Cancer Diagnostics
|
February 27, 2024
A connection between IDC in prostate biopsy specimens and a lymph node metastatic propensity in PSMA PET or CT?
Read More
PSMA-dRT: Imaging Prior to Radiation for Intermediate-, High-Risk Prostate Cancer
Jérémie Calais, MD, PhD
Prostate Cancer Diagnostics
|
March 21, 2024
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
View More
SAR-bisPSMA Is Safe, Effective in Detecting Tumors in Patients With Prostate Cancer
Zachary Bessette
Prostate Cancer Diagnostics
|
February 15, 2024
Initial data from the COBRA trial confirm that 64Cu-SAR-bisPSMA is safe and “highly” effective in detecting BCR PC.
Read More
PSMA PET: Current Sensitivity and A Novel Approach
Judd W. Moul, MD
ASCO GU Symposium 2024
|
January 30, 2024
Dr. Moul offered his insights on how prostate cancer MRI and PSMA PET compare in terms of utility and sensitivity.
View More
Load More
Advertisement
Advertisement
Advertisement